NEW YORK (GenomeWeb) – An economic model evaluating the impact of Myriad Genetics' Prolaris test on a hypothetical prostate cancer cohort found that the multi-gene expression diagnostic reduced costs by $2,850 per patient tested, which extrapolated over a 10-year period could amount to $6 billion in savings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.